Drug-eluting stents: Results, promises and problems

International Journal of Cardiology

Volumn 99, Issue 1, 2005, Pages 9-17

  Van Der Hoeven, Barend L ^a   Pires, Nuno M M ^a,b   Warda, Hazem M ^a   Oemrawsingh, Pranobe V ^a   Van Vlijmen, Bart J M ^a,b   Quax, Paul H A ^b   Schalij, Martin J ^a   Van Der Wall, Ernst E ^a   Jukema, J Wouter ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Drug eluting stents; Paclitaxel; Restenosis; Side effects; Sirolimus

Indexed keywords

7 HEXANOYLTAXOL; ABCIXIMAB; ABT 578; ANGIOPEPTIN; ANTIINFECTIVE AGENT; BATIMASTAT; CILOSTAZOL; CYCLOSPORIN; CYTOCHALASIN D; DACTINOMYCIN; DEXAMETHASONE; ESTRADIOL; EVEROLIMUS; LATRUNCULIN A; MAMMALIAN TARGET OF RAPAMYCIN; MYCOPHENOLIC ACID; NITRIC OXIDE; PACLITAXEL; PACLITAXEL DERIVATIVE; RAPAMYCIN; TACROLIMUS; TRANILAST; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTERY INTIMA PROLIFERATION; CANCER; CELL CYCLE; CELL CYCLE G1 PHASE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELUTING STENT; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HUMAN; INFLAMMATION; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SMOOTH MUSCLE FIBER; THROMBOCYTE ACTIVATION; TREATMENT FAILURE;

EID: 13844308657     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2004.01.021     Document Type: Review

References (61)

1. Landau C., Lange R.A., Hillis L.D. Percutaneous transluminal coronary angioplasty. N. Engl. J. Med. 330(14):1994;981-993
2. Mintz G.S., Popma J.J., Pichard A.D., Kent K.M., Satler L.F., Wong C., et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. 94(1):1996;35-43
3. Fischman D.L., Leon M.B., Baim D.S., Schatz R.A., Savage M.P., Penn I., et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N. Engl. J. Med. 331(8):1994;496-501
4. Kiemeneij F., Serruys P.W., Macaya C., Rutsch W., Heyndrickx G., Albertsson P., et al. Continued benefit of coronary stenting versus balloon angioplasty: five-year clinical follow-up of Benestent-I trial. J. Am. Coll. Cardiol. 37(6):2001;1598-1603
5. Lowe H.C., Oesterle S.N., Khachigian L.M. Coronary in-stent restenosis: current status and future strategies. J. Am. Coll. Cardiol. 39(2):2002;183-193
6. Hoffmann R., Mintz G.S., Dussaillant G.R., Popma J.J., Pichard A.D., Satler L.F., et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation. 94(6):1996;1247-1254
7. Grewe P.H., Deneke T., Machraoui A., Barmeyer J., Muller K.M. Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. J. Am. Coll. Cardiol. 35(1):2000;157-163
8. Farb A., Sangiorgi G., Carter A.J., Walley V.M., Edwards W.D., Schwartz R.S., et al. Pathology of acute and chronic coronary stenting in humans. Circulation. 99(1):1999;44-52
9. Kornowski R., Hong M.K., Tio F.O., Bramwell O., Wu H., Leon M.B. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J. Am. Coll. Cardiol. 31(1):1998;224-230
10. Brasen J.H., Kivela A., Roser K., Rissanen T.T., Niemi M., Luft F.C., et al. Angiogenesis, vascular endothelial growth factor and platelet-derived growth factor-BB expression, iron deposition, and oxidation-specific epitopes in stented human coronary arteries. Arterioscler. Thromb. Vasc. Biol. 21(11):2001;1720-1726
11. Kimura T., Abe K., Shizuta S., Odashiro K., Yoshida Y., Sakai K., et al. Long-term clinical and angiographic follow-up after coronary stent placement in native coronary arteries. Circulation. 105(25):2002;2986-2991
12. Glover C., Ma X., Chen Y.X., Miller H., Veinot J., Labinaz M., et al. Human in-stent restenosis tissue obtained by means of coronary atherectomy consists of an abundant proteoglycan matrix with a paucity of cell proliferation. Am. Heart J. 144(4):2002;702-709
13. Chung I.M., Gold H.K., Schwartz S.M., Ikari Y., Reidy M.A., Wight T.N. Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. J. Am. Coll. Cardiol. 40(12):2002;2072-2081
14. Kuroda N., Kobayashi Y., Nameki M., Kuriyama N., Kinoshita T., Okuno T., et al. Intimal hyperplasia regression from 6 to 12 months after stenting. Am. J. Cardiol. 89(7):2002;869-872
15. Salame M.Y., Verheye S., Crocker I.R., Chronos N.A., Robinson K.A., King S.B. III Intracoronary radiation therapy. Eur. Heart J. 22(8):2001;629-647
16. Faxon D.P. Systemic drug therapy for restenosis: "deja vu all over again" Circulation. 106(18):2002;2296-2298
17. Versaci F., Gaspardone A., Tomai F., Ribichini F., Russo P., Proietti I., et al. Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS Study). J. Am. Coll. Cardiol. 40(11):2002;1935-1942
18. Fujita M., Mizuno K., Ho M., Tsukahara R., Miyamoto A., Miki O., et al. Sarpogrelate treatment reduces restenosis after coronary stenting. Am. Heart J. 145(3):2003;E16
19. Lincoff A.M., Topol E.J., Ellis S.G. Local drug delivery for the prevention of restenosis. Fact, fancy, and future. Circulation. 90(4):1994;2070-2084
20. Wohrle J., Al Khayer E., Grotzinger U., Schindler C., Kochs M., Hombach V., et al. Comparison of the heparin coated vs the uncoated Jostent - no influence on restenosis or clinical outcome. Eur. Heart J. 22(19):2001;1808-1816
21. Lovich M.A., Creel C., Hong K., Hwang C.W., Edelman E.R. Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel. J. Pharm. Sci. 90(9):2001;1324-1335
22. Hwang C.W., Wu D., Edelman E.R. Physiological transport forces govern drug distribution for stent-based delivery. Circulation. 104(5):2001;600-605
23. van der Giessen W.J., Lincoff A.M., Schwartz R.S., van Beusekom H.M., Serruys P.W., Holmes D.R. Jr., et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 94(7):1996;1690-1697
24. Drachman D.E., Edelman E.R., Seifert P., Groothuis A.R., Bornstein D.A., Kamath K.R., et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J. Am. Coll. Cardiol. 36(7):2000;2325-2332
25. Suzuki T., Kopia G., Hayashi S., Bailey L.R., Llanos G., Wilensky R., et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 104(10):2001;1188-1193
26. Lewis A.L., Stratford P.W. Phosphorylcholine-coated stents. J. Long-Term Eff. Med. Implants. 12(4):2002;231-250
27. Palmaz J.C., Bailey S., Marton D., Sprague E. Influence of stent design and material composition on procedure outcome. J. Vasc. Surg. 36(5):2002;1031-1039
28. Tamai H., Igaki K., Kyo E., Kosuga K., Kawashima A., Matsui S., et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 102(4):2000;399-404
29. Finkelstein A., McClean D., Kar S., Takizawa K., Varghese K., Baek N., et al. Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation. 107(5):2003;777-784
30. Marx S.O., Marks A.R. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation. 104(8):2001;852-855
31. Morice M.C., Serruys P.W., Sousa J.E., Fajadet J., Ban H.E., Perin M., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346(23):2002;1773-1780
32. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349(14):2003;1315-1323
33. Schofer J., Schluter M., Gershlick A.H., Wijns W., Garcia E., Schampaert E., et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 362(9390):2003;1093-1099
34. Rowinsky E.K., Donehower R.C., et al. Paclitaxel (taxol). N. Engl. J. Med. 332(15):1995;1004-1014
35. Gershlick A.H. European evaLUation of pacliTaxel eluting Stent (ELUTES). Circulation. 105(5):2002;E39
36. Park S.J., Shim W.H., Ho D.S., Raizner A.E., Park S.W., Hong M.K., et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N. Engl. J. Med. 348(16):2003;1537-1545
37. Grube E., Silber S., Hauptmann K.E., Mueller R., Buellesfeld L., Gerckens U., et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 107:2003;38-42
38. Colombo A., Drzewiecki J., Banning A., Grube E., Hauptmann K., Silber S., et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 108(7):2003;788-794
39. de La Fuente L.M., Miano J., Mrad J., Penaloza E., Yeung A.C., Eury R., et al. Initial results of the Quanam drug eluting stent (QuaDS-QP-2) registry (BARDDS) in human subjects. Catheter. Cardiovasc. Interv. 53(4):2001;480-488
40. Honda Y., Grube E., de La Fuente L.M., Yock P.G., Stertzer S.H., Fitzgerald P.J. Novel drug-delivery stent: intravascular ultrasound observations from the first human experience with the QP2-eluting polymer stent system. Circulation. 104(4):2001;380-383
41. Kataoka T., Grube E., Hauptmann K.E., Hur S.H., Morino Y., Hassan A.H.M., et al. Prevention of restenosis by a new drug eluting stent: an intravascular ultrasound substudy of the SCORE trial. Circulation. 104(17):2001;3307
42. Liistro F., Colombo A. Late acute thrombosis after paclitaxel eluting stent implantation. Heart. 86(3):2001;262-264
43. Abizaid A.A., New G., Abizaid A.S., Costa M., Vaz V., Kipshidze N., et al. First clinical experience with 17-estradiol-eluting BiodivYsio matrix LO stent to prevent restenosis in de-novo native coronary arteries: six-month clinical outcomes and angiographic follow-up from the EASTER trial. J. Am. College Cardiol. 41(6):2003;56A
44. Shirota T., Yasui H., Shimokawa H., Matsuda T. Fabrication of endothelial progenitor cell (EPC)-seeded intravascular stent devices and in vitro endothelialization on hybrid vascular tissue. Biomaterials. 24(13):2003;2295- 2302
45. Kutryk M.J.B., Kuliszewski M.A. Progenitor cell capture for the accelerated endothelialization of endovascular devices. Am. J. Cardiol. 90(6A):2002;TCT180
46. Degertekin M., Regar E., Tanabe K., Smits P.C., van der Giessen W.J., Carlier S.G., et al. Sirolimus-eluting stent for treatment of complex in-stent restenosis. The first clinical experience. J. Am. Coll. Cardiol. 41(2):2003;184-189
47. Liistro F., Stankovic G., Di Mario C., Takagi T., Chieffo A., Moshiri S., et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation. 105(16):2002;1883-1886
48. Sousa J.E., Costa M.A., Abizaid A., Sousa A.G., Feres F., Mattos L.A., et al. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 107(1):2003;24-27
49. Tanabe K., Serruys P.W., Grube E., Smits P.C., Selbach G., van der Giessen W.J., et al. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation. 107(4):2003;559-564
50. Virmani R., Kolodgie F.D., Farb A., Lafont A. Drug eluting stents: are human and animal studies comparable? Heart. 89(2):2003;133-138
51. Long-term effects of stent-based delivery of sirolimus in the porcine model. Am. J. Cardiol. 90(6A):2002;TCT199
52. Babinska A., Markell M.S., Salifu M.O., Akoad M., Ehrlich Y.H., Kornecki E. Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol. Dial. Transplant. 13(12):1998;3153-3159
53. Lemos P.A., Lee C.H., Degertekin M., Saia F., Tanabe K., Arampatzis C.A., et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. J. Am. Coll. Cardiol. 41(11):2003;2093-2099
54. Lee C.H., Lemos P.A., Van Domburg R.T., Sianos G., Smits P.C., van der Giessen W.J., et al. Safety and efficacy of sirolimus-eluting stent (cypher) in acute myocardial infarction: a substudy of the rapamycin-eluting stent evaluation at Rotterdam cardiology hospital (RESEARCH) study. J. Am. Coll. Cardiol. 41(6):2003;21A
55. FDA Public Health Web Notification: Information for Physicians on Sub-acute Thromboses (SAT) and Hypersensitivity Reactions with Use of the Cordis CYPHER™ Coronary Stent. 29-10-2003.
56. Curcio A., Torella D., Cuda G., Coppola C., Faniello M.C., Achille F., et al. Effect of stent coating alone on in vitro vascular smooth muscle cell proliferation and apoptosis. Am. J. Physiol. Heart Circ. Physiol. 28b:2004;902-908
57. Lemos P.A., Saia F., Ligthart J.M., Arampatzis C.A., Sianos G., Tanabe K., et al. Coronary restenosis after sirolimus-eluting stent implantation. Morphological description and mechanistic analysis from a consecutive series of cases. Circulation. 108:2003;257-260
58. Colombo A., Orlic D., Stankovic G., Corvaja N., Spanos V., Montorfano M., et al. Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation. Circulation. 107(17):2003;2178-2180
59. Cutlip D.E., Chauhan M.S., Baim D.S., Ho K.K., Popma J.J., Carrozza J.P., et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J. Am. Coll. Cardiol. 40(12):2002;2082-2089
60. Morice M.C., Aubry P., Benveniste E., Bourdonnec C., Commeau P. The MUST trial: acute results and six-month clinical follow-up. J. Invasive Cardiol. 10(8):1998;457-463
61. de Jaegere P., Mudra H., Figulla H., Almagor Y., Doucet S., Penn I., et al. Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study). Eur. Heart J. 19(8):1998;1214-1223